Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1161/JAHA.115.002584 http://scihub22266oqcxt.onion/10.1161/JAHA.115.002584 C4859376!4859376 !26738790     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 278.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 278.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26738790 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Am+Heart+Assoc 2016 ; 5 (1 ): ä Nephropedia Template TP {{tp|p=26738790 |t=2016. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort |pdf=|usr=}}{{26738790 }} gab.com Text Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort JO: J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=26738790 #FOAvip BACKGROUND: Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear. In this study, we address the use of these 3 ?-blockers and their associations with mortality. METHODS AND RESULTS: Long-term hemodialysis patients, aged ?35 years, with new-onset heart failure and receiving various medications were identified through the use of 1999-2010 data from the Taiwan National Health Insurance Research Database. From the total of 4435 heart failure patients, we selected 1700 new users of the 3 ?-blockers (study group) and 1700 nonusers (control group), by using matched cohorts according to their propensity scores, and then compared the 5-year all-cause mortality rates by using Cox proportional hazard regressions and time-dependent covariate adjustment. During 3944 person-years of follow-up, 666 (39.2%) deaths occurred within the study group, compared with 918 (54%) deaths during 2893 person-years of follow-up in the control group. The 5-year mortality rate for the study (control) group was 54.5% (70.3%); P<0.001. Adjusted hazard regression analyses revealed that the therapeutic effects of ?-blockers remained significant for all-cause mortality (hazard ratio 0.80, 95% CI 0.72 to 0.90). Subgroup analyses revealed that patients in the study group receiving ?-blockers plus renin-angiotensin system antagonists exhibited the lowest mortality rate, while the highest mortality rate was found among patients in the control group receiving neither ?-blockers nor renin-angiotensin system antagonists. CONCLUSIONS: This study demonstrates that the 3 ?-blockers were associated with improved survival in long-term hemodialysis patients with heart failure. Twit Text FOAVip Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort ????J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=26738790 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26738790 #FOAvip English Wikipedia <ref>{{Cite pmid|26738790 }}</ref> Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort #MMPMID26738790 Tang CH ; Wang CC ; Chen TH ; Hong CY ; Sue YM J Am Heart Assoc 2016[Jan]; 5 (1 ): ä PMID26738790 show ga BACKGROUND: Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear. In this study, we address the use of these 3 ?-blockers and their associations with mortality. METHODS AND RESULTS: Long-term hemodialysis patients, aged ?35 years, with new-onset heart failure and receiving various medications were identified through the use of 1999-2010 data from the Taiwan National Health Insurance Research Database. From the total of 4435 heart failure patients, we selected 1700 new users of the 3 ?-blockers (study group) and 1700 nonusers (control group), by using matched cohorts according to their propensity scores, and then compared the 5-year all-cause mortality rates by using Cox proportional hazard regressions and time-dependent covariate adjustment. During 3944 person-years of follow-up, 666 (39.2%) deaths occurred within the study group, compared with 918 (54%) deaths during 2893 person-years of follow-up in the control group. The 5-year mortality rate for the study (control) group was 54.5% (70.3%); P<0.001. Adjusted hazard regression analyses revealed that the therapeutic effects of ?-blockers remained significant for all-cause mortality (hazard ratio 0.80, 95% CI 0.72 to 0.90). Subgroup analyses revealed that patients in the study group receiving ?-blockers plus renin-angiotensin system antagonists exhibited the lowest mortality rate, while the highest mortality rate was found among patients in the control group receiving neither ?-blockers nor renin-angiotensin system antagonists. CONCLUSIONS: This study demonstrates that the 3 ?-blockers were associated with improved survival in long-term hemodialysis patients with heart failure. |*Renal Dialysis/adverse effects/mortality [MESH] |Adrenergic beta-Antagonists/adverse effects/chemistry/*therapeutic use [MESH] |Adult [MESH] |Aged [MESH] |Angiotensin II Type 1 Receptor Blockers/therapeutic use [MESH] |Angiotensin-Converting Enzyme Inhibitors/therapeutic use [MESH] |Bisoprolol/adverse effects/chemistry/*therapeutic use [MESH] |Carbazoles/adverse effects/chemistry/*therapeutic use [MESH] |Carvedilol [MESH] |Chi-Square Distribution [MESH] |Databases, Factual [MESH] |Delayed-Action Preparations [MESH] |Drug Compounding [MESH] |Female [MESH] |Heart Failure/diagnosis/*drug therapy/mortality [MESH] |Humans [MESH] |Kaplan-Meier Estimate [MESH] |Kidney Failure, Chronic/diagnosis/mortality/*therapy [MESH] |Male [MESH] |Metoprolol/adverse effects/chemistry/*therapeutic use [MESH] |Middle Aged [MESH] |Multivariate Analysis [MESH] |Propanolamines/adverse effects/chemistry/*therapeutic use [MESH] |Propensity Score [MESH] |Proportional Hazards Models [MESH] |Retrospective Studies [MESH] |Risk Factors [MESH] |Taiwan [MESH] |Time Factors [MESH]Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controll(epmc).pdf DeepDyve Pubget Overpricing